<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.targetedonc.com/view/neladalkib-fda-approval-alk-positive-nsclc</loc>
      <lastmod>2026-11-17T19:03:26.761Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T19:03:26.761Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/anito-cel-post-car-t-burden-neurotoxicity</loc>
      <lastmod>2026-11-17T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Dr Frigault on Anito-Cel’s Potential to Reduce Post CAR T Burden]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-fast-tracks-onvansertib-for-first-line-ras-mutated-mcrc</loc>
      <lastmod>2026-11-17T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Fast Tracks Onvansertib for First-Line RAS-Mutated mCRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/daraxonrasib-pancreatic-cancer-aguirre-ras-inhibitor</loc>
      <lastmod>2026-11-17T16:01:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:01:00Z</news:publication_date>
        <news:title><![CDATA[Dr Aguirre on Daraxonrasib Bringing RAS-Targeted Therapy to Pancreatic Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/lenvatinib-pembrolizumab-yields-40-month-os-in-pretreated-thymic-tumors</loc>
      <lastmod>2026-11-17T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Lenvatinib/Pembrolizumab Yields 40-Month OS in Pretreated Thymic Tumors]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/managing-drug-interactions-and-acid-suppression</loc>
      <lastmod>2026-11-17T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Managing Drug Interactions and Acid Suppression]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/psychiatric-history-and-family-planning-in-treatment-selection</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Psychiatric History and Family Planning in Treatment Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/ligibel-bwel-weight-loss-quality-of-life-breast-cancer</loc>
      <lastmod>2026-11-17T10:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T10:00:00Z</news:publication_date>
        <news:title><![CDATA[Dr Ligibel on Quality-of-Life Gains From the BWEL Weight Loss Program in Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/giredestrant-everolimus-fda-approval-esr1-breast-cancer</loc>
      <lastmod>2026-11-17T12:49:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:33:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/early-diffuse-tgct-recurrence-puts-systemic-therapy-trade-offs-in-focus</loc>
      <lastmod>2026-11-16T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Early Diffuse TGCT Recurrence Puts Systemic Therapy Trade-Offs in Focus]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-approves-pertuzumab-biosimilar-her2-positive-breast-cancer</loc>
      <lastmod>2026-11-17T16:06:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Pertuzumab Biosimilar in HER2-Positive Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/tumor-treating-fields-improve-pain-quality-of-life-pancreatic-cancer</loc>
      <lastmod>2026-11-16T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T17:00:00Z</news:publication_date>
        <news:title><![CDATA[Tumor Treating Fields Improve Pain and Quality of Life in Pancreatic Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/cretostimogene-pivot-006-phase-3-intermediate-risk-nmibc</loc>
      <lastmod>2026-11-16T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/neuroendocrine-tumors-specialty-center-referral-lewis</loc>
      <lastmod>2026-11-16T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Dr Lewis on When to Refer Patients With NETs to a Specialty Center]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/detalimogene-legend-trial-bcg-unresponsive-nmibc-updated-data</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Detalimogene Demonstrates Durability in NMIBC, Supporting BLA Submission]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-does-not-approve-ivonescimab-for-egfr-mutant-nsclc-harmoni</loc>
      <lastmod>2026-11-15T23:19:38.232Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T23:19:38.232Z</news:publication_date>
        <news:title><![CDATA[FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/crossover-to-bezuclastinib-plus-sunitinib-improves-disease-control-in-pretreated-gist</loc>
      <lastmod>2026-11-15T22:34:19.489Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-15T22:34:19.489Z</news:publication_date>
        <news:title><![CDATA[Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST]]></news:title>
      </news:news>
	</url></urlset>